Key facts
- This page summarizes William H. Chang's Form 4 filing for Ensysce Biosciences, Inc. (ENSC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Jun 2022, 17:47.
William H. Chang - 23 Jun 2022 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- ENSC
- Reported as of
- 23 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jun 2022, 17:47:22 UTC
- Prior SEC filing
- 04 Feb 2022
- Next SEC filing
- 07 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Chang
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William H. Chang filed Form 4 for Ensysce Biosciences, Inc. (ENSC) on 27 Jun 2022.
Change
- Previous filing in this sequence was filed on 04 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENSC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 353,451
- Date
- 23 Jun 2022
- Ownership
- Direct
ENSC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,242,189
- Date
- 23 Jun 2022
- Ownership
- By Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENSC
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +15,000
- Change %
- +75%
- Price
- Shares after
- 35,000
- Date
- 23 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $0.4250
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On June 23, 2022, Mr. Chang was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.